Циркулирајући нуклеарни фактор-Капа Б посредује упала повезана са раком у карциному дојке и дебелог црева

Нуклеарни фактор-каппа Б код рака дојке и дебелог црева

  • Hafize Uzun Istanbul University-Cerrahpasa
  • Berrin Papila Kundaktepe
  • Volkan Sozer
  • Pinar Kocael
  • Sinem Durmus
  • Dilara Kurtulus
  • Cigdem Papila
  • Remise Gelisgen
DOI: https://doi.org/10.5937/jomb0-27128
Ključne reči: Nuclear factor kappa-B, tumor necrosis factor-α, soluble TNF-related apoptosis inducing ligand, Interleukin-6, Pentraxin-3

Sažetak


Позадина: Упала је препозната као карактеристична карактеристика развоја и напредовања рака. Циљ наше студије био је да се истражи значај серумског нивоа нуклеарног фактора каппа-Б (НФ-кБ) као циркулирајући маркер у монитору упале рака дојке и дебелог црева; приказати однос између НФ-кБ са инфламаторним параметрима као фактором некрозе тумора-α (ТНФ-α), растворљивим ТНФ-сродном апоптозом која индукује лиганд (сТРАИЛ), интерлеукин-6 (ИЛ-6), пентраксин-3 (ПТКС-3 ), нивоа прокалцитонина (ПЦТ) и Ц-реактивног протеина (ЦРП). Методе: Нивои серума НФ-кБ, ТНФ-α, сТРАИЛ, ИЛ-6, ПТКС-3, ПЦТ и нивоа ЦРП у серуму мерени су коришћењем ензима који је повезан са имуносорбентом (ЕЛИСА) код 40 пацијената са карциномом дојке, 40 пацијената са карциномом дебелог црева и 30 здравих контрола. Резултати: Концентрација НФ-кБ, ТНФ-α, ИЛ-6, ПТКС-3, ПЦТ и ЦРП у серуму била је значајно већа, а концентрација сТРАИЛ у серуму била је значајно нижа код пацијената са карциномом дојке и дебелог црева него код оних са здравом контролом . НФ-кБ су били у позитивној корелацији са ЦРП и негативни језгри са сТРАИЛ. Закључци: Ови резултати сугерирају да повећани НФ-кБ може умањити клиничку ефикасност сТРАИЛ-а у чврстим ћелијама тумора. Постоји веза између упале и карциногенезе тако да се развој карцинома дешава са хроничном упалом дојке и дебелог црева. Резултати студије су показали да пацијенти са карциномом дебелог црева и дојке имају појачану системску упалу, мерено повећаним циркулирајућим цитокинима и протеинима акутне фазе, или неправилностима у ћелијама у циркулацији. НФ-кБ се може комбиновати са другим маркерима системског инфламаторног одговора у прогностичким резултатима рака. Поред хируршке ресекције тумора, конвенционална радио- и хемотерапија за лечење рака, употреба сТРАИЛ-а или других агониста за терапију рака појавила се као нова потенцијална терапија.

Reference

1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454: 436-44.
2. West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol. 2015; 15: 615-29.
3. Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 2013; 12: 86.
4. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007; 8: 49-62.
5. Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer. 2010; 102: 639-44.
6. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011; 48: 155-70.
7. Zhou B, Shu B, Yang J, Liu J, Xi T, Xing Y. C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis. Cancer Causes Control. 2014; 25: 1397-405.
8. Guo L, Liu S, Zhang S, Chen Q, Zhang M, Quan P, Lu J, Sun X. C-reactive protein and risk of breast cancer: A systematic review and meta-analysis. Sci Rep. 2015; 5: 10508.
9. Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms J Autoimmun. 2017 Dec;85:58-63.
10. Sbrana A, Torchio M, Comolli G, Antonuzzo A, Danova M; Italian Network for Supportive Care in Oncology (NICSO). Use of procalcitonin in clinical oncology: a literature review. New Microbiol. 2016; 39: 174-180.
11. Mérino D1, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets. 2007; 11: 1299-314.
12. Prajoko YW, Aryandono T Expression of nuclear factor kappa B (NF-κB) as a predictor of poor pathologic response to chemotherapy in patients with locally advanced breast cancer.. Asian Pac J Cancer Prev. 2014; 15: 595-8.
13. Coussens LM Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
14. Shacter E, Weitzman SA. Chronic Inflammation and Cancer. Oncology 2002; 16: 217–226.
15. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 11: 1175-1183.
16. Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine. 2008; 43: 374-9.
17. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, Sandler RS. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 2008; 68: 323-8.
18. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, Ben-Baruch A. Inflammatory mediators in breast cancer: coordinated expression of TNF- & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 2011; 11: 130.
19. Madhusudan S1, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol. 2005; 23: 5950-9.
20. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003; 103: 642-6.
21. Xu J1, Ye Y, Zhang H, Szmitkowski M, Mäkinen MJ, Li P, Xia D, Yang J, Wu Y, Wu H. Diagnostic and prognostic value of serum ınterleukin-6 in colorectal cancer. Medicine (Baltimore). 2016; 95: e2502.
22. Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Sato M, Takeyama H. Preoperative Serum Interleukin-6 Is a Potential Prognostic Factor for Colorectal Cancer, including Stage II Patients. Gastroenterol Res Pract. 2016; 2016: 9701574.
23. Chung YC, Chaen YL, Hsu CP. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res. 2006; 26: 3905-11.
24. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer. 1999; 85: 2526-31.
25. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003; 83: 222-6.
26. Yeh KY, Li YY, Hsieh LL, Lu CH, Chou WC, Liaw CC, Tang RP, Liao SK. Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer. Jpn J Clin Oncol. 2010; 40: 580-7.
27. Berberoglu U, Yildirim E, Celen O. Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. Int J Biol Markers. 2004; 19: 130-4.
28. Stanilov N, Miteva L, Dobreva Z, Stanilova S. Colorectal cancer severity and survival in correlation with tumour necrosis factor-alpha. Biotechnol Biotechnol Equip. 2014; 28: 911-917.
29. Grimm M, Lazariotou M, Kircher S, H€ofelmayr A, Germer CT, von Rahden BHA, Waaga-Gasser AM, Gasser M. Tumor necrosis factor-a is associated with positive lymph node status in patients with recurrence of colorectal cancer - indications for anti-TNF- agents in cancer treatment. Cell Oncol. 2010; 33: 151-163.
30. Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke S. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer. 2008; 7: 331-337.
31. Tang D, Tao D, Fang Y, Deng C, Xu Q, Zhou J. TNF-Alpha Promotes Invasion and Metastasis via NF-Kappa B Pathway in Oral Squamous Cell Carcinoma. Med Sci Monit Basic Res. 2017; 23: 141-149.
32. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5: 157-63.
33. Kelley SK1, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther. 2001; 299: 31-8.
34. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 2002; 62: 5800-6.
35. Toiyama D, Takaha N, Shinnoh M, Ueda T, Kimura Y, Nakamura T, Hongo F, Mikami K, Kamoi K, Kawauchi A, Miki T. Significance of serum tumor necrosis factor-related apoptosis-inducing ligand as a prognostic biomarker for renal cell carcinoma. Mol Clin Oncol. 2013; 1: 69-74.
36. Tecchio C, Huber V, Scapini P, et al: IFNalpha-stimulated neutro-phils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 103: 3837-3844, 2004.
37. Tanaka H, Ito T, Kyo T and Kimura A: Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients. Eur J Haematol 2007; 78: 389-398,.
38. Perik PJ, Van der Graaf WT, De Vries EG, et al: Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors. Acta Oncol 45: 175-183, 2006.
39. Luo JL, Maeda S, Hsu LC, et al. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004; 6: 297–305
40. Kwon HC, Kim SH, Oh SY, Lee S, Kwon KA, Lee JH, Choi HJ, Park KJ, Lee HS, Roh MS, Kim HJ. Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer. Cancer Sci. 2010; 101: 1557-61.
41. Slattery ML, Mullany LE, Sakoda L, Samowitz WS, Wolff RK, Stevens JR, Herrick JS. The NF-κB signalling pathway in colorectal cancer: associations between dysregulated gene and miRNA expression. J Cancer Res Clin Oncol. 2018;144: 269-283.
42. Giacomini A, Ghedini GC, Presta M, Ronca R. Long pentraxin 3: a novel multifaceted player in cancer. Biochim Biophys Acta Rev Cancer. (2018); 1869: 53-63.
43. Diamandis EP, Goodglick L, Planque C, Thornquist MD. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res. 2011;17: 2395–9.
44. Choi B, Lee E-J, Song D-H, Yoon S-C, Chung Y-H, Jang Y, et al. Elevated pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function. Oncotarget. 2014; 5: 481-92.
45. Chen WY, Wu F, You ZY, Zhang ZM, Guo YL, Zhong LX. Analyzing the differentially expressed genes and pathway cross-talk in aggressive breast cancer. J Obstet Gynaecol Res. 2015; 41: 132–40.
46. Player A, Abraham N, Burrell K, Bengone IO, Harris A, Nunez L, et al. Identification of candidate genes associated with triple negative breast cancer. Genes Cancer. 2017; 8: 659-72.
47. Basu S, Harris H, Wolk A, Rossary A, Caldefie-Chézet F, Vasson MP, Larsson A. Inflammatory F2-isoprostane, prostaglandin F2α, pentraxin 3 levels and breast cancer risk: The Swedish Mammography Cohort. Prostaglandins Leukot Essent Fatty Acids. 2016; 113: 28-32.
48. Zhang J, Wang TY, Niu XC. Increased plasma levels of Pentraxin 3 are associated with poor prognosis of colorectal carcinoma patients. Tohoku J Exp Med. 2016; 240: 39-46.
49. Liu B, Zhao Y, Guo L. Increased serum pentraxin-3 level predicts poor prognosis in patients with colorectal cancer after curative surgery, a cohort study. Medicine. 2018; 97: e11780.
50. Durnaś B, Wątek M, Wollny T, Niemirowicz K, Marzec M, Bucki R, Góźdź S. Utility of blood procalcitonin concentration in the management of cancer patients with infections. Onco Targets Ther. 2016; 9: 469-75.
Objavljeno
2020/09/11
Broj časopisa
Vol. 40 Br. 2 (2021): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2020 Hafize Uzun, Berrin Papila Kundaktepe, Volkan Sozer, Pinar Kocael, Sinem Durmus, Dilara Kurtulus, Cigdem Papila, Remise Gelisgen

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.